{"id":419652,"date":"2021-01-22T13:33:08","date_gmt":"2021-01-22T18:33:08","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=419652"},"modified":"2021-01-22T13:33:08","modified_gmt":"2021-01-22T18:33:08","slug":"aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/","title":{"rendered":"AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, Jan.\u00a022, 2021 \/PRNewswire\/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that on January 22, 2021<\/span>, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00<\/span> minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2). The Company regained compliance with the NASDAQ’s requirements when the closing bid price for the Company’s common stock was at or above $1.00<\/span> for 10 consecutive business days and the matter is now closed.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/AIkido
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“We are fully committed to maintaining our Nasdaq listing and value the opportunity to reach a large and diverse community of investors as we continue our efforts to deploy our artificial intelligences technologies for the development of effective pharmaceutical solutions,” commented Mr. Anthony Hayes<\/span>, CEO of AIkido. <\/p>\n

\n About AIkido Pharma Inc.
<\/b>AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.\u00a0 The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The\u00a0University of Texas<\/span> at Austin\u00a0and\u00a0Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.\u00a0 The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.<\/p>\n

\n Forward-Looking Statements<\/b>\n <\/p>\n

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n

\n Contact:<\/b>\n <\/p>\n

Investor Relations:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n

Hayden IR
Brett Maas<\/span>, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com<\/a>
www.haydenir.com<\/a><\/p>\n

AIkido Pharma Inc.:\u00a0\u00a0\u00a0 <\/p>\n

Phone: 212-745-1373
Email: investorrelations@aikidopharma.com<\/a>
www.aikidopharma.com<\/a><\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-301213309.html<\/a><\/p>\n

SOURCE AIkido Pharma Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, Jan.\u00a022, 2021 \/PRNewswire\/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that on January 22, 2021, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2). The Company regained compliance with the NASDAQ’s requirements when the closing bid price for the Company’s common stock was at or above $1.00 for 10 consecutive business days and the matter is now closed. “We are fully committed to maintaining our Nasdaq listing and value the opportunity to reach a large and diverse community of investors … <\/p>\n

Continue reading “AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-419652","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Jan.\u00a022, 2021 \/PRNewswire\/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that on January 22, 2021, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2). The Company regained compliance with the NASDAQ’s requirements when the closing bid price for the Company’s common stock was at or above $1.00 for 10 consecutive business days and the matter is now closed. “We are fully committed to maintaining our Nasdaq listing and value the opportunity to reach a large and diverse community of investors … Continue reading "AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-22T18:33:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements\",\"datePublished\":\"2021-01-22T18:33:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\\\/\"},\"wordCount\":487,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1138079\\\/Aikida_Pharma_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\\\/\",\"name\":\"AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1138079\\\/Aikida_Pharma_Logo.jpg\",\"datePublished\":\"2021-01-22T18:33:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1138079\\\/Aikida_Pharma_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1138079\\\/Aikida_Pharma_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/","og_locale":"en_US","og_type":"article","og_title":"AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements - Market Newsdesk","og_description":"PR Newswire NEW YORK, Jan.\u00a022, 2021 \/PRNewswire\/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that on January 22, 2021, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2). The Company regained compliance with the NASDAQ’s requirements when the closing bid price for the Company’s common stock was at or above $1.00 for 10 consecutive business days and the matter is now closed. “We are fully committed to maintaining our Nasdaq listing and value the opportunity to reach a large and diverse community of investors … Continue reading \"AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-22T18:33:08+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements","datePublished":"2021-01-22T18:33:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/"},"wordCount":487,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/","name":"AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg","datePublished":"2021-01-22T18:33:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/419652","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=419652"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/419652\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=419652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=419652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=419652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}